Alexion Pharmaceuticals, Inc.

Release Summary

Alexion Pharmaceuticals today announced that researchers will present new interim data from a Phase 1/2 dose-escalation study of ALXN1210 at the 58th ASH Annual Meeting.

Alexion Pharmaceuticals, Inc.